The injectable therapy setmelanotide, being developed by Rhythm Pharmaceuticals for Prader-Willi syndrome (PWS), curbs hyperphagia, or uncontrollable hunger,…
Articles by Steve Bryson, PhD
Bright Minds Biosciences has launched a clinical program to evaluate whether its oral therapy candidate BMB-105 can ease hyperphagia,…
Soleno Therapeutics plans to help accelerate research toward finding a genetic cure for Prader-Willi syndrome (PWS). “We will commit…
Aardvark Therapeutics has amended the protocol for the Phase 3 HERO clinical trial testing ARD-101, its investigational oral therapy…
Targeting an enzyme called EHMT2 may help treat Prader-Willi syndrome (PWS) by reactivating the maternal PWS genes that are…
Relmada Therapeutics is working toward the launch, next year, of a Phase 2 clinical trial to test sepranolone —…
People with Prader-Willi Syndrome (PWS) experience worse depression, overall health, and life satisfaction compared with the general population, according…
The extended-release formulation of diazoxide choline (DCCR) — approved in the U.S. earlier this year for use in…
The U.S. Food and Drug Administration (FDA) has delayed by three months its decision on whether to approve Soleno…
Hospitalizations among people with Prader-Willi syndrome (PWS) are characterized by higher healthcare utilization and complexity compared with non-PWS patients,…